{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T10:37:20Z","timestamp":1762079840122,"version":"3.37.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T00:00:00Z","timestamp":1651190400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T00:00:00Z","timestamp":1651190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100015841","name":"Nordic Nanovector ASA","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100015841","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100005366","name":"University of Oslo","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005366","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Imaging Biol"],"published-print":{"date-parts":[[2022,10]]},"abstract":"<jats:title>Abstract\n<\/jats:title><jats:sec>\n                <jats:title>\nPurpose\n<\/jats:title>\n                <jats:p>[<jats:sup>177<\/jats:sup>Lu]Lu-lilotomab satetraxetan, a novel CD37 directed radioimmunotherapy (RIT), has been investigated in a first-in-human phase 1\/2a study for relapsed indolent non-Hodgkin lymphoma. In this study, new methods were assessed to calculate the mean absorbed dose to the total tumor volume, with the aim of establishing potential dose\u2013response relationships based on 2-deoxy-2-[18F]fluoro-<jats:sc>d<\/jats:sc>-glucose (FDG) positron emission tomography (PET) parameters and clinical response. Our second aim was to study if higher total tumor burden induces reduction in the <jats:sup>177<\/jats:sup>Lu-lilotomab satetraxetan accumulation in tumor.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Procedures\n<\/jats:title>\n                <jats:p>Fifteen patients with different pre-dosing (non-radioactive lilotomab) regimens were included and the cohort was divided into low and high non-radioactive lilotomab pre-dosing groups for some of the analyses. <jats:sup>177<\/jats:sup>Lu-lilotomab satetraxetan was administered at dosage levels of 10, 15, or 20\u00a0MBq\/kg. Mean absorbed doses to the total tumor volume (<jats:italic>tTAD<\/jats:italic>) were calculated from posttreatment single-photon emission tomography (SPECT)\/computed tomography (CT) acquisitions. Total values of metabolic tumor volume (<jats:italic>tMTV<\/jats:italic>), total lesion glycolysis (<jats:italic>tTLG<\/jats:italic>) and the percent change in these parameters were calculated from FDG PET\/CT performed at baseline, and at 3 and 6\u00a0months after RIT. Clinical responses were evaluated at 6\u00a0months as complete remission (CR), partial remission (PR), stable disease (SD), or progressive disease (PD).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Significant decreases in <jats:italic>tMTV<\/jats:italic> and <jats:italic>tTLG<\/jats:italic> were observed at 3\u00a0months for patients receiving <jats:italic>tTAD<\/jats:italic>\u2009\u2265\u2009200\u00a0cGy compared to patients receiving <jats:italic>tTAD<\/jats:italic>\u2009&lt;\u2009200\u00a0cGy (<jats:italic>p<\/jats:italic>\u2009=\u2009.03 for both). All non-responders had <jats:italic>tTAD<\/jats:italic>\u2009&lt;\u2009200\u00a0cGy. Large variations in <jats:italic>tTAD<\/jats:italic> were observed in responders. Reduction in <jats:sup>177<\/jats:sup>Lu-lilotomab satetraxetan uptake in tumor volume was not observed in patients with higher baseline tumor burden (tTMV).<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p><jats:italic>tTAD<\/jats:italic> of\u2009\u2265\u2009200\u00a0cGy may prove valuable to ensure clinical response, but further studies are needed to confirm this in a larger patient population. Furthermore, this work indicates that higher baseline tumor burden (up to 585 cm<jats:sup>3<\/jats:sup>) did not induce reduction in radioimmunoconjugate accumulation in tumor.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1007\/s11307-022-01731-3","type":"journal-article","created":{"date-parts":[[2022,4,29]],"date-time":"2022-04-29T15:03:58Z","timestamp":1651244638000},"page":"807-817","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["FDG PET\/CT and Dosimetric Studies of 177Lu-Lilotomab Satetraxetan in a First-in-Human Trial for Relapsed Indolent non-Hodgkin Lymphoma\u2014Are We Hitting the Target?"],"prefix":"10.1007","volume":"24","author":[{"given":"Ayca","family":"L\u00f8ndalen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johan","family":"Blakkisrud","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mona-Elisabeth","family":"Revheim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jostein","family":"Dahle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arne","family":"Kolstad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Stokke","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2022,4,29]]},"reference":[{"issue":"8","key":"1731_CR1","doi-asserted-by":"publisher","first-page":"2825","DOI":"10.1200\/JCO.1998.16.8.2825","volume":"16","author":"P McLaughlin","year":"1998","unstructured":"McLaughlin P, Grillo-Lopez AJ, Link BK, Levy R, Czuczman MS, Williams ME et al (1998) Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: half of patients respond to a four-dose treatment program. J Clin Oncol 16(8):2825\u20132833. https:\/\/doi.org\/10.1200\/JCO.1998.16.8.2825","journal-title":"J Clin Oncol"},{"issue":"1","key":"1731_CR2","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1016\/j.critrevonc.2006.09.004","volume":"62","author":"G Cartron","year":"2007","unstructured":"Cartron G, Blasco H, Paintaud G, Watier H, Le Guellec C (2007) Pharmacokinetics of rituximab and its clinical use: thought for the best use? Crit Rev Oncol Hematol 62(1):43\u201352. https:\/\/doi.org\/10.1016\/j.critrevonc.2006.09.004","journal-title":"Crit Rev Oncol Hematol"},{"issue":"16","key":"1731_CR3","doi-asserted-by":"publisher","first-page":"3765","DOI":"10.1182\/blood-2008-08-175125","volume":"113","author":"D Dayde","year":"2009","unstructured":"Dayde D, Ternant D, Ohresser M, Lerondel S, Pesnel S, Watier H et al (2009) Tumor burden influences exposure and response to rituximab: pharmacokinetic-pharmacodynamic modeling using a syngeneic bioluminescent murine model expressing human CD20. Blood 113(16):3765\u20133772. https:\/\/doi.org\/10.1182\/blood-2008-08-175125","journal-title":"Blood"},{"issue":"19","key":"1731_CR4","doi-asserted-by":"publisher","first-page":"2616","DOI":"10.1182\/blood-2016-10-744292","volume":"129","author":"M Tout","year":"2017","unstructured":"Tout M, Casasnovas O, Meignan M, Lamy T, Morschhauser F, Salles G et al (2017) Rituximab exposure is influenced by baseline metabolic tumor volume and predicts outcome of DLBCL patients: a Lymphoma Study Association report. Blood 129(19):2616\u20132623. https:\/\/doi.org\/10.1182\/blood-2016-10-744292","journal-title":"Blood"},{"issue":"6","key":"1731_CR5","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1097\/MNM.0b013e3282f813a4","volume":"29","author":"A Berkowitz","year":"2008","unstructured":"Berkowitz A, Basu S, Srinivas S, Sankaran S, Schuster S, Alavi A (2008) Determination of whole-body metabolic burden as a quantitative measure of disease activity in lymphoma: a novel approach with fluorodeoxyglucose-PET. Nucl Med Commun 29(6):521\u2013526. https:\/\/doi.org\/10.1097\/MNM.0b013e3282f813a4","journal-title":"Nucl Med Commun"},{"issue":"2","key":"1731_CR6","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1007\/s00259-014-2961-x","volume":"42","author":"R Boellaard","year":"2015","unstructured":"Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W et al (2015) FDG PET\/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging 42(2):328\u201354. https:\/\/doi.org\/10.1007\/s00259-014-2961-x","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"1731_CR7","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.2967\/jnumed.110.075176","volume":"51","author":"YK Dewaraja","year":"2010","unstructured":"Dewaraja YK, Schipper MJ, Roberson PL, Wilderman SJ, Amro H, Regan DD et al (2010) 131I-tositumomab radioimmunotherapy: initial tumor dose-response results using 3-dimensional dosimetry including radiobiologic modeling. J Nucl Med 51(7):1155\u20131162. https:\/\/doi.org\/10.2967\/jnumed.110.075176","journal-title":"J Nucl Med"},{"issue":"7","key":"1731_CR8","doi-asserted-by":"publisher","first-page":"1047","DOI":"10.2967\/jnumed.113.136044","volume":"55","author":"YK Dewaraja","year":"2014","unstructured":"Dewaraja YK, Schipper MJ, Shen J, Smith LB, Murgic J, Savas H et al (2014) Tumor-absorbed dose predicts progression-free survival following (131)I-tositumomab radioimmunotherapy. J Nucl Med 55(7):1047\u20131053. https:\/\/doi.org\/10.2967\/jnumed.113.136044","journal-title":"J Nucl Med"},{"issue":"4","key":"1731_CR9","doi-asserted-by":"publisher","first-page":"417","DOI":"10.1089\/cbr.2008.0568","volume":"24","author":"YK Dewaraja","year":"2009","unstructured":"Dewaraja YK, Wilderman SJ, Koral KF, Kaminski MS, Avram AM (2009) Use of integrated SPECT\/CT imaging for tumor dosimetry in I-131 radioimmunotherapy: a pilot patient study. Cancer Biother Radiopharm 24(4):417\u2013426. https:\/\/doi.org\/10.1089\/cbr.2008.0568","journal-title":"Cancer Biother Radiopharm"},{"issue":"17","key":"1731_CR10","doi-asserted-by":"publisher","first-page":"4091","DOI":"10.1182\/bloodadvances.2020002583","volume":"4","author":"A Kolstad","year":"2020","unstructured":"Kolstad A, Illidge T, Bolstad N, Spetalen S, Madsbu U, Stokke C et al (2020) Phase 1\/2a study of 177Lu-lilotomab satetraxetan in relapsed\/refractory indolent non-Hodgkin lymphoma. Blood Adv 4(17):4091\u20134101. https:\/\/doi.org\/10.1182\/bloodadvances.2020002583","journal-title":"Blood Adv"},{"issue":"6","key":"1731_CR11","doi-asserted-by":"publisher","first-page":"1902","DOI":"10.1007\/s00259-020-05098-x","volume":"48","author":"A Londalen","year":"2021","unstructured":"Londalen A, Blakkisrud J, Revheim ME, Madsbu UE, Dahle J, Kolstad A et al (2021) FDG PET\/CT parameters and correlations with tumor-absorbed doses in a phase 1 trial of (177)Lu-lilotomab satetraxetan for treatment of relapsed non-Hodgkin lymphoma. Eur J Nucl Med Mol Imaging 48(6):1902\u20131914. https:\/\/doi.org\/10.1007\/s00259-020-05098-x","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"7","key":"1731_CR12","doi-asserted-by":"publisher","first-page":"1233","DOI":"10.1007\/s00259-018-3964-9","volume":"45","author":"C Stokke","year":"2018","unstructured":"Stokke C, Blakkisrud J, Londalen A, Dahle J, Martinsen ACT, Holte H et al (2018) Pre-dosing with lilotomab prior to therapy with (177)Lu-lilotomab satetraxetan significantly increases the ratio of tumor to red marrow absorbed dose in non-Hodgkin lymphoma patients. Eur J Nucl Med Mol Imaging 45(7):1233\u20131241. https:\/\/doi.org\/10.1007\/s00259-018-3964-9","journal-title":"Eur J Nucl Med Mol Imaging"},{"issue":"1","key":"1731_CR13","doi-asserted-by":"publisher","first-page":"48","DOI":"10.2967\/jnumed.116.173922","volume":"58","author":"J Blakkisrud","year":"2017","unstructured":"Blakkisrud J, Londalen A, Martinsen AC, Dahle J, Holtedahl JE, Bach-Gansmo T et al (2017) Tumor-absorbed dose for non-hodgkin lymphoma patients treated with the anti-CD37 antibody radionuclide conjugate 177Lu-lilotomab satetraxetan. J Nucl Med 58(1):48\u201354. https:\/\/doi.org\/10.2967\/jnumed.116.173922","journal-title":"J Nucl Med"},{"issue":"3","key":"1731_CR14","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.icrp.2008.10.001","volume":"38","author":"K Eckerman","year":"2008","unstructured":"Eckerman K, Endo A (2008) ICRP Publication 107 Nuclear decay data for dosimetric calculations. Ann Icrp 38(3):7\u201396","journal-title":"Ann Icrp"},{"issue":"4","key":"1731_CR15","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","volume":"17","author":"BD Cheson","year":"1999","unstructured":"Cheson BD, Horning SJ, Coiffier B, Shipp MA, Fisher RI, Connors JM et al (1999) Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas NCI Sponsored International Working Group. J Clin Oncol 17(4):1244","journal-title":"J Clin Oncol"},{"issue":"5","key":"1731_CR16","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","volume":"25","author":"BD Cheson","year":"2007","unstructured":"Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ et al (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25(5):579\u2013586. https:\/\/doi.org\/10.1200\/JCO.2006.09.2403","journal-title":"J Clin Oncol"},{"key":"1731_CR17","doi-asserted-by":"publisher","first-page":"e144","DOI":"10.1038\/psp.2014.42","volume":"3","author":"E Gibiansky","year":"2014","unstructured":"Gibiansky E, Gibiansky L, Carlile DJ, Jamois C, Buchheit V, Frey N (2014) Population pharmacokinetics of obinutuzumab (GA101) in chronic lymphocytic leukemia (CLL) and non-Hodgkin\u2019s lymphoma and exposure-response in CLL. Cpt Pharmacometrics Syst Pharmacol 3:e144. https:\/\/doi.org\/10.1038\/psp.2014.42","journal-title":"Cpt Pharmacometrics Syst Pharmacol"},{"issue":"9","key":"1731_CR18","doi-asserted-by":"publisher","first-page":"2002","DOI":"10.1111\/bcp.13991","volume":"85","author":"D Ternant","year":"2019","unstructured":"Ternant D, Monjanel H, Venel Y, Prunier-Aesch C, Arbion F, Colombat P et al (2019) Nonlinear pharmacokinetics of rituximab in non-Hodgkin lymphomas: a pilot study. Br J Clin Pharmacol 85(9):2002\u20132010. https:\/\/doi.org\/10.1111\/bcp.13991","journal-title":"Br J Clin Pharmacol"},{"issue":"7","key":"1731_CR19","doi-asserted-by":"publisher","first-page":"1412","DOI":"10.1182\/blood-2008-08-175653","volume":"113","author":"TM Illidge","year":"2009","unstructured":"Illidge TM, Bayne M, Brown NS, Chilton S, Cragg MS, Glennie MJ et al (2009) Phase 1\/2 study of fractionated (131)I-rituximab in low-grade B-cell lymphoma: the effect of prior rituximab dosing and tumor burden on subsequent radioimmunotherapy. Blood 113(7):1412\u20131421. https:\/\/doi.org\/10.1182\/blood-2008-08-175653","journal-title":"Blood"},{"issue":"3","key":"1731_CR20","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.cpet.2019.03.002","volume":"14","author":"L Kostakoglu","year":"2019","unstructured":"Kostakoglu L, Chauvie S (2019) PET-derived quantitative metrics for response and prognosis in lymphoma. PET Clin 14(3):317\u2013329. https:\/\/doi.org\/10.1016\/j.cpet.2019.03.002","journal-title":"PET Clin"},{"key":"1731_CR21","doi-asserted-by":"publisher","unstructured":"Islam P Goldstein J Flowers CR. 2019 PET-derived tumor metrics predict DLBCL response and progression-free survival. Leuk Lymphoma.:1\u20137.\u00a0https:\/\/doi.org\/10.1080\/10428194.2018.1562181.","DOI":"10.1080\/10428194.2018.1562181"},{"issue":"19","key":"1731_CR22","doi-asserted-by":"publisher","first-page":"6935","DOI":"10.1088\/0031-9155\/61\/19\/6935","volume":"61","author":"S Marcatili","year":"2016","unstructured":"Marcatili S, Pichard A, Courteau A, Ladjohounlou R, Navarro-Teulon I, Repetto-Llamazares A et al (2016) Realistic multi-cellular dosimetry for (177)Lu-labelled antibodies: model and application. Phys Med Biol 61(19):6935\u20136952. https:\/\/doi.org\/10.1088\/0031-9155\/61\/19\/6935","journal-title":"Phys Med Biol"},{"issue":"2","key":"1731_CR23","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1016\/j.beha.2012.04.004","volume":"25","author":"AP Skarbnik","year":"2012","unstructured":"Skarbnik AP, Smith MR (2012) Radioimmunotherapy in mantle cell lymphoma. Best Pract Res Clin Haematol 25(2):201\u2013210. https:\/\/doi.org\/10.1016\/j.beha.2012.04.004","journal-title":"Best Pract Res Clin Haematol"},{"issue":"2","key":"1731_CR24","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1002\/hon.882","volume":"27","author":"RL Haas","year":"2009","unstructured":"Haas RL (2009) Low dose radiotherapy in indolent lymphomas, enough is enough. Hematol Oncol 27(2):71\u201381. https:\/\/doi.org\/10.1002\/hon.882","journal-title":"Hematol Oncol"}],"container-title":["Molecular Imaging and Biology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-022-01731-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11307-022-01731-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11307-022-01731-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T07:19:24Z","timestamp":1666163964000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11307-022-01731-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,29]]},"references-count":24,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["1731"],"URL":"https:\/\/doi.org\/10.1007\/s11307-022-01731-3","relation":{},"ISSN":["1536-1632","1860-2002"],"issn-type":[{"type":"print","value":"1536-1632"},{"type":"electronic","value":"1860-2002"}],"subject":[],"published":{"date-parts":[[2022,4,29]]},"assertion":[{"value":"8 November 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 March 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 April 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 April 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"\u201cAll procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.\u201d","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"Arne Kolstad was in part supported by grants from the Norwegian Cancer Society. Arne Kolstad is member of the Scientific Advisory Board of Nordic Nanovector ASA. Jostein Dahle is an employee and shareholder of Nordic Nanovector ASA. Ayca L\u00f8ndalen has no conflict of interest. Johan Blakkisrud has received grants from South-Eastern Norway Regional Health Authority during the conduct of the study. Mona-Elisabeth Revheim has no conflict of interest. Caroline Stokke has no conflict of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}}]}}